{"id":"isoniazid-h","safety":{"commonSideEffects":[{"rate":"1-2","effect":"Peripheral neuropathy"},{"rate":"0.5-3","effect":"Hepatotoxicity"},{"rate":"0.1-0.5","effect":"Hypersensitivity reactions"},{"rate":"0.1-0.2","effect":"Drug-induced lupus"},{"rate":null,"effect":"Pyridoxine deficiency"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid is a prodrug that requires activation by the mycobacterial enzyme catalase-peroxidase (KatG) to form an isonicotinoyl radical. This activated form binds to mycobacterial enoyl-ACP reductase (InhA), inhibiting the synthesis of mycolic acids that are critical structural components of the mycobacterial cell wall. This disruption of cell wall integrity leads to bacterial death and is bactericidal against actively dividing M. tuberculosis.","oneSentence":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:19.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (active and latent infection)"},{"name":"Drug-susceptible pulmonary and extrapulmonary tuberculosis"}]},"trialDetails":[{"nctId":"NCT06568484","phase":"PHASE2, PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":"Tuberculosis, Latent","enrollment":2530},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07163143","phase":"PHASE3","title":"Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2025-11","conditions":"Tuberculosis (TB)","enrollment":784},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT07058090","phase":"PHASE1","title":"Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi","status":"NOT_YET_RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07","conditions":"Drug Induced Liver Injury, Tuberculosis (TB)","enrollment":410},{"nctId":"NCT04260477","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimen","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-03-01","conditions":"Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":370},{"nctId":"NCT06727864","phase":"PHASE3","title":"Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial","status":"RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2024-01-01","conditions":"Pulmonary Tuberculosis","enrollment":270},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":"Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis","enrollment":309},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT04176250","phase":"PHASE2","title":"Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2020-01-16","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT02554318","phase":"NA","title":"Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2013-11","conditions":"Pulmonary Tuberculosis, Body Weight Changes, Motor Activity","enrollment":147},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT02958709","phase":"PHASE1, PHASE2","title":"Optimizing Treatment to Improve TBM Outcomes in Children","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-22","conditions":"Tuberculosis, Meningeal","enrollment":38},{"nctId":"NCT02231229","phase":"PHASE4","title":"Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-07-23","conditions":"Tuberculosis","enrollment":204},{"nctId":"NCT03862248","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More","status":"WITHDRAWN","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-09-30","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT00933790","phase":"PHASE3","title":"Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2009-09-14","conditions":"HIV Infection, Pulmonary TB","enrollment":331},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT02457208","phase":"PHASE1","title":"PK Study of Anti-TB Drugs","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-07-07","conditions":"Tuberculosis","enrollment":61},{"nctId":"NCT03230409","phase":"NA","title":"Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents","status":"COMPLETED","sponsor":"Hospital Sant Joan de Deu","startDate":"2014-01-01","conditions":"Tuberculosis","enrollment":359},{"nctId":"NCT02313610","phase":"PHASE2","title":"Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-04","conditions":"Pulmonary Tuberculosis","enrollment":253},{"nctId":"NCT01225640","phase":"PHASE2","title":"PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay","status":"COMPLETED","sponsor":"Sequella, Inc.","startDate":"2011-08","conditions":"Tuberculosis","enrollment":59},{"nctId":"NCT02496572","phase":"","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-09","conditions":"Multidrug Resistant Tuberculosis","enrollment":110},{"nctId":"NCT00495326","phase":"PHASE2, PHASE3","title":"Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-12","conditions":"Tuberculosis, Aids, Hiv Infections","enrollment":570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":176,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INH"],"phase":"phase_3","status":"active","brandName":"Isoniazid (H)","genericName":"Isoniazid (H)","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival. Used for Tuberculosis (active and latent infection), Drug-susceptible pulmonary and extrapulmonary tuberculosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}